Monitoring immune-mediated inflammatory diseases (IMIDs), including rheumatoid arthritis (RA), is essential because of complex pathophysiological and cholinergic mechanisms associated with them and the need for various therapeutic interventions. Toxoplasmosis is a zoonotic parasitic infection which is considered a risk factor in IMIDs.

Aim of the study: Assessment of the role of therapy in RA and other IMIDs patients through evaluation of plasma levels of inflammatory indicators interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP), and oxidative stress markers malondialdehyde (MDA) and total antioxidant status (TAS), and plasma cholinesterase (ChE) activity. Also, examining the connection of toxoplasmosis with disease activity and therapies in patients with IMIDs and the impact of therapy on the revival of dormant toxoplasmosis.

PhD researcher: Rabie Gabriel Abdullah

PhD thesis in Clinical Pharmacology